Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
April 25 2022 - 5:06PM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced two poster presentations at the 32nd
European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID) being held April 23-26, 2022 in Lisbon, Portugal.
The poster presentations at ECCMID were as
follows:
- Title: In Vitro Activity of Sulopenem and
Comparator Agents Against Anaerobic Clinical Isolates from the
SENTRY Surveillance Program 2018-2020Presenting
Author: Steven AroninPoster Session: 5a.
Mechanisms of action, new compounds, preclinical data &
pharmacology of antibacterial agents
- Title: Efficacy and Safety of Intravenous
Sulopenem Followed by Oral Sulopenem Etzadroxil/Probenecid Versus
Intravenous Ertapenem Followed by Oral Ciprofloxacin and
Metronidazole or Amoxicillin-Clavulanate in the Treatment of
Complicated Intra-abdominal Infections: The SURE-3
TrialPresenting Author: Steven
AroninPoster Session: 5c. New or repurposed
antibacterial agents: clinical trials
These Posters can be found on the Company’s
website on the “Publications: Posters & Presentations” page
under the “Our Science” tab.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical
company dedicated to developing differentiated anti-infectives
aimed at combatting the global crisis of multi-drug resistant
pathogens to significantly improve the lives of people affected by
serious and life-threatening diseases around the world. Iterum is
currently advancing its first compound, sulopenem, a novel penem
anti-infective compound, in Phase 3 clinical development with an
oral formulation. Sulopenem also has an IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum has received Qualified Infectious Disease
Product (QIDP) and Fast Track designations for its oral and IV
formulations of sulopenem in seven indications. For more
information, please visit http://www.iterumtx.com.
Forward-Looking Statements
This press release contains forward-looking
statements. These forward-looking statements include, without
limitation, statements regarding the development, therapeutic and
market potential of sulopenem. In some cases, forward-looking
statements can be identified by words such as “may,” “believes,”
“intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,”
“should,” “assumes,” “continues,” “could,” “would,” “will,”
“future,” “potential” or the negative of these or similar terms and
phrases. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause Iterum’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements.
Forward-looking statements include all matters that are not
historical facts. Actual future results may be materially different
from what is expected due to factors largely outside Iterum’s
control, including uncertainties inherent in the initiation and
conduct of clinical and non-clinical development, including any
potential additional clinical trials and non-clinical development
that may be conducted in response to the complete response letter
received by Iterum in July 2021, availability and timing of data
from such potential clinical and non-clinical development, changes
in regulatory requirements or decisions of regulatory authorities,
the timing or likelihood of regulatory filings and approvals,
including any potential resubmission of the new drug application
for oral sulopenem, changes in public policy or legislation,
commercialization plans and timelines, if oral sulopenem is
approved, the actions of third-party clinical research
organizations, suppliers and manufacturers, the accuracy of
Iterum’s expectations regarding how far into the future Iterum’s
cash on hand will fund Iterum’s ongoing operations including
completing potential additional clinical and non-clinical
development of oral sulopenem, the impact of COVID-19 and related
responsive measures thereto, Iterum’s ability to maintain its
listing on the Nasdaq Stock Market, risks and uncertainties
concerning the outcome, impact, effects and results of Iterum’s
evaluation of corporate, strategic, financial and financing
alternatives, including the terms, timing, structure, value,
benefits and costs of any corporate, strategic, financial or
financing alternative and Iterum’s ability to complete one at all
and other factors discussed under the caption “Risk Factors” in its
Annual Report on Form 10-K filed with the Securities and Exchange
Commission (the “SEC”) on March 28, 2022, and other documents filed
with the SEC from time to time. Forward-looking statements
represent Iterum’s beliefs and assumptions only as of the date of
this press release. Except as required by law, Iterum assumes no
obligation to update these forward-looking statements publicly, or
to update the reasons actual results could differ materially from
those anticipated in the forward-looking statements, even if new
information becomes available in the future.
Investor Contact:Judy
MatthewsChief Financial Officer 312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Apr 2023 to Apr 2024